News Release
- June 8, 2010
- RELEASE OF "MUCODYNE® DS50%"
- May 26, 2010
- Change of Business Name
- May 26, 2010
- New Medium-Term Business Plan Developed: "HOPE 100 Stage 1"
- February 3, 2010
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
- January 18, 2010
- MARKETING APPROVAL FOR "MUCODYNE® DS50%"
- January 7, 2010
- Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
- November 5, 2009
- Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
- September 29, 2009
- KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
- August 5, 2009
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
- July 27, 2009
- Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
- April 3, 2009
- Change of Representative Director and President at KYORIN Pharmaceutical
- April 3, 2009
- Change of Representative Director and President at KYORIN
- March 19, 2009
- KYORIN Announces Dissolution of Subsidiary
- March 19, 2009
- KYORIN Subsidiary (Investment LPS) to Be Dissolved
- February 27, 2009
- Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
- February 5, 2009
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2009
- February 4, 2009
- KYORIN Updates Credit Rating from R&I
- January 29, 2009
- Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008
- December 24, 2008
- Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
- October 1, 2008
- Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
1 2
